IPV-Boostrix suspension for injection in pre-filled syringe

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/11/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 19/11/2020

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
Medicine Name Bexsero, suspension for injection in pre-filled syringe Active Ingredients Meningococcal group-B vaccine (rDNA, component, adsorbed)
Medicine Name Boostrix - Suspension for injection Active Ingredients Diphtheria, Tetanus and Pertussis vaccine
1 - 0 of 135 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 November 2020

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Updated on 19 November 2020 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 19 August 2020

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

Updated the warning statement regarding administration in subjects with thrombocytopenia (see section 4.3) or a bleeding disorder to include subcutaneous injection, with the consequential update to the statement regarding applying firm pressure, to read as follows:

If in accordance with official recommendations, the vaccine may be administered subcutaneously to these subjects. With both routes of administration, firm pressure should be applied to the injection site (without rubbing) for at least two minutes.

Updated on 5 February 2019

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Change to section 4.6 – Fertility, pregnancy and lactation
Added the statement 'For data relating to the prevention of pertussis disease in infants born to women vaccinated during pregnancy, see section 5.1', and moved the statement 'The use of IPV-Boostrix may be considered during the third trimester of pregnancy' to the start of the 'Pregnancy' subsection.
 

Updated on 28 February 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 28 February 2018 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 – Special warnings and precautions for use:
Clarified the warning on convulsions to ‘a history of febrile convulsions’

Change to section 4.8 – Undesirable effects:
Added the following statement under the subheading ‘Reactogenicity after repeat dose’:
Subjects aged 15 years onwards without recent vaccination for diphtheria, tetanus, pertussis and poliomyelitis, who received a dose of IPV-Boostrix or another reduced-antigen content vaccine, followed by an additional dose of IPV-Boostrix 10 years after, showed no increased reactogenicity after this second dose compared to the first one.

Change to section 5.1 – Pharmacodynamic properties:
Persistence of the antibodies ten years after a first dose of IPV-Boostrix administered in adolescence or adulthood, Immunogenicity and tolerability of a second dose of IPV-Boostrix administered ten years after the first dose.

Updated on 9 May 2017 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 5.1 – Pharmacodynamic properties
Under the subheading 'Immune response in subjects without prior or with unknown vaccination history', the number of subjects (adolescents aged from 11 to 18 years) described as having received Boostrix was reduced from 123 to 83. As a consequence, the sensitivity of the analysis changed, resulting in the revision of the range of variability of the seropositivity rate for the different pertussis antigens after one dose, changed from between 90% and 98% to 87% and 100%.

Change to section 4.8 – Undesirable effects
Under 'Clinical trials', added the subheading 'Reactogenicity after repeat dose' and moved the corresponding text from its previous position under 'Post marketing surveillance' to under the new subheading.

Updated on 23 January 2017 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.1 Therapeutic indications

·                Changed the minimum age from 4 years to 3 years

·                Deleted the statement ‘IPV-Boostrix is not intended for primary immunisation’

 Change to section 4.2 – Posology and method of administration

Posology

·                Changed the minimum age from 4 years to 3 years

·                Added the statement: ‘The use of IPV-Boostrix may be considered during the third trimester of pregnancy. For the use of the vaccine before the third trimester of pregnancy, see section 4.6’

·                Revised the description of the antigen content of diphtheria, tetanus and pertussis from ‘low adult dose’ to ‘reduced content

·                Replaced the statements regarding vaccination of adults with the following: ‘IPV-Boostrix may be administered to adolescents and adults with unknown vaccination status or incomplete vaccination against diphtheria, tetanus and pertussis as part of an immunisation series against diphtheria, tetanus, pertussis and poliomyelitis. Based on data in adults, two additional doses of a diphtheria and tetanus containing vaccine are recommended one and six months after the first dose to maximize the vaccine response against diphtheria and tetanus (see section 5.1)’

·                Updated the term for the antigen ‘poliomyelitis’ from ‘polio’

·                Under the subheading ‘Paediatric population’ updated the statement to take the reduced age indication of 3 years to read: ‘The safety and efficacy of IPV-Boostrix in children below 3 years of age have not been established’

 

Change to section 4.3 – Contraindications

·                Updated the term for the antigen ‘poliomyelitis’ from ‘polio’

·         Revised the spelling of ‘contraindicated’ and ‘contraindication’ (removed hyphenation)

 

Change to section 4.4 – Special warnings and precautions for use

·                Revised the spelling of ‘contraindication’ (removed hyphenation)

 

Change to section 4.5 – Interaction with other medicinal products and other forms of interaction

·                Added measles, mumps, rubella and varicella as monovalent or combination vaccines that may be administered concomitantly with IPV-Boostrix

·                Added the acronyms (MMR/V) and (HPV)

 Change to section 4.6 – Pregnancy and lactation

·                Reorganised the order of the text along the sequence of ‘Pregnancy’, Breastfeeding’ and ‘Fertility’

·                Under the subheading ‘Pregnancy’, replaced the existing statements (lack of data for use in pregnancy, risk based use of vaccine in pregnancy and no expected harm to the foetus), with the following:

o    Safety data from a prospective observational study where Boostrix (dTpa component of IPV-Boostrix) was administered to pregnant women during the third trimester (793 pregnancy outcomes) as well as data from passive surveillance where pregnant women were exposed to IPV-Boostrix or to Boostrix in the 3rd and 2nd trimester have shown no vaccine related adverse effect on pregnancy or on the health of the foetus/newborn child

o    The use of IPV-Boostrix may be considered during the third trimester of pregnancy.

o    Human data from prospective clinical studies on the use of IPV-Boostrix during the first and second trimester of pregnancy are not available. However, as with other inactivated vaccines, it is not expected that vaccination with IPV-Boostrix harms the foetus at any trimester of pregnancy. The benefits versus the risks of administering IPV-Boostrix during pregnancy should be carefully evaluated.

 Change to section 4.8 – Undesirable effects

·                Added the following subheading and statements regarding the coadministration with MMR/V in children aged 3-6 years

Coadministration with MMR/V vaccines in children aged 3-6 years

IPV-Boostrix was coadministered with MMR/V vaccines in 2 clinical studies with 406 children aged 3-6 years. In these studies, upper respiratory tract infection and rash were commonly reported. Fever, irritability, fatigue, loss of appetite and gastrointestinal disorders (including diarrhoea and vomiting) were reported with a higher frequency (very common) when compared to Table 1 while all other adverse reactions occurred at the same or lower frequency

·                Formatting and typographical updates to align with the current formatting requirements of the QRD Template, including the tabulation of adverse reactions.

 Change to section 5.1 – Pharmacodynamic properties

·                Updated the table representing the immune responses after one month post vaccination with IPV-Boostrix as observed across clinical studies, to include children aged 3-8 years and adults and adolescents aged 10 years and older (previously ‘subjects’ aged 4-8 years and ‘subjects’ aged 10-93 years)

·                Added the following subheading and statement regarding the immune response in subjects without prior or with unknown vaccination history:

Immune response in subjects without prior or with unknown vaccination history

After administration of one dose of Boostrix (dTpa component of IPV-Boostrix) to 123 adolescents aged from 11 to 18 years, without previous pertussis vaccination and no vaccination against diphtheria and tetanus in the previous 5 years, all subjects were seroprotected against tetanus and diphtheria. The seropositivity rate after one dose varied between 90% and 98% for the different pertussis antigens.

·         Formatting update, to include the following subheadings:

Immune response

Persistence of the immune response

Immune response after a repeat dose of IPV-Boostrix or Boostrix

Immune response in subjects without prior or with unknown vaccination history

Efficacy in protecting against pertussis

Updated on 19 January 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 19 January 2017 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - dose and frequency
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 4 September 2015 SPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8 : IMB name change to HPRA. 

Update to section  10 : change of revision date

Updated on 3 September 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 17 July 2015 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - Change to address of the Irish MA Holder from Stonemasons Way, Rathfarnham, Dublin 16 to 12 Riverwalk, Citywest Business Campus, Dublin 24.

 
Section 10 - change to date of revision of text.

Updated on 16 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 25 February 2014 SPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.6      Fertility, pregnancy and lactation

Updated the statement regarding fertility to specify that no human data from prospective clinical studies are available, and added the advice:

Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see section 5.3).

 

Updated the information regarding use in Pregnancy, specifying that no human data are available and referred to data from animal studies and that IPV-Boostrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus, i.e.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development (see section 5.3).

 

As with other inactivated vaccines, it is not expected that vaccination with IPV-Boostrix harms the foetus.

 

However, human data from prospective clinical studies on the use of IPV-Boostrix during pregnancy are not available. Therefore, IPV-Boostrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus. No teratogenic effect of vaccines containing diphtheria or tetanus toxoids, or inactivated poliovirus has been observed following use in pregnant women.

 

4.8      Undesirable effects

Clarified that all of the the side effects reported during post-marketing surveillance are relevant to IPV-Boostrix.

 

Changed the system organ class for the side effect ‘angiodema’ from ‘Blood and lymphatic system’ to ‘Skin and subcutaneous tissue disorders’

 

Added the the IMB Pharmacovigilance details for the reporting of adverse events, i.e.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions preferably through the online reporting option accessible from the IMB homepage.  A downloadable report form is also accessible from the IMB website, which may be completed manually and submitted to the IMB via ‘freepost’. Alternatively, the traditional post-paid ‘yellow card’ option may also continue to be used.

 

FREEPOST

Pharmacovigilance Section

Irish Medicines Board

Kevin O’Malley House

Earlsfort Centre

Earlsfort Terrace

Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie

 

5.3      Preclinical safety data

Added new sub-heading ‘Reproductive toxicology’ with new statements regarding fertility and pregnancy, and added new sub-heading Animal toxicology and/or pharmacology to the previously approved statement ‘Preclinical data reveal no special hazard for humans based on conventional studies of safety and of toxicity’, to read:

Reproductive toxicology

 

Fertility

 

Non-clinical data obtained with IPV-Boostrix reveal no specific hazard for humans based on conventional studies of female fertility in rats and rabbits.

 

Pregnancy

 

Non-clinical data obtained with IPV-Boostrix reveal no specific hazard for humans based on conventional studies of embryo-foetal development in rats and rabbits, and also of parturition and postnatal toxicity in rats (up to the end of the lactation period).

 

Animal toxicology and/or pharmacology

 

Preclinical data reveal no special hazard for humans based on conventional studies of safety and of toxicity.

 

Updated on 25 February 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 16 January 2013 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4     Special warnings and precautions for use

Added the following warning regarding syncope:

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Updated on 15 January 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change due to harmonisation of PIL
  • Change due to user-testing of patient information

Updated on 10 January 2012 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to Sections: 2,  4.2,  4.3,  4.4,  4.5,  4.6,  4.8,  4.9

Updated on 5 January 2012 PIL

Reasons for updating

  • Change to side-effects

Updated on 25 August 2011 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 15 February 2011 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.2       Posology and method of administration

Under the subheading ‘posology’, replaced the following paragraph:

Individuals with an incomplete, or no, history of a primary series of diphtheria and tetanus toxoids should not be vaccinated with IPV-Boostrix. IPV-Boostrix is not precluded in subjects with an incomplete, or no, history of previous pertussis or polio vaccination.  However a booster response will only be elicited in individuals who have been previously primed by vaccination or by natural infection.

with the following:

In subjects ³ 40 years of age that had not received any diphtheria or tetanus containing vaccine in the past 20 years (including those who have never been vaccinated or whose vaccination status was unknown), one dose of IPV-Boostrix induces an antibody response against pertussis and protects against tetanus and diphtheria in the majority of cases. Two additional doses of a diphtheria and tetanus containing vaccine will maximize the vaccine response against diphtheria and tetanus when administered one and six months after the first dose (see section 5.1).

Deleted the following:

There are no data on the duration of protection against pertussis following vaccination with IPV-Boostrix.

Added pertussis to the following sentence:

Repeat vaccination against diphtheria, tetanus, pertussis and poliomyelitis should be performed at intervals as per official recommendations.

 

 

4.4       Special warnings and precautions for use

Removed reference to ‘infant’ in the following sentence:

As for any vaccination, the risk-benefit of immunising with IPV-Boostrix or deferring this vaccination should be weighed carefully in an infant or in a child suffering from a new onset or progression of a severe neurological disorder.

 

 

4.6       Fertility, pregnancy and lactation

Updated the heading to include ‘fertility.

 

 

4.8       Undesirable effects

Corrected the spelling for ‘pruritus’

 

Under the subheading Post-marketing surveillance, replaced the statement

The reactogenicity of revaccination with IPV-Boostrix has not been evaluated.

with

Data suggest that in subjects with DTP in childhood a booster dose might give an increase of local reactogenicity.

 

 

5.1       Pharmacodynamic properties

Added data on seroprotection / seropositivity rates for five years following a first vaccination of children 4 to 8 years of age with IPV-Boostrix

 

Added data on seroprotection / seropositivity rates for three to 3.5 years, 5 and 10 years following a first vaccination with Boostrix (dTpa component of IPV-Boostrix)

 

Added the following statements regarding immunogenicity:

The immunogenicity of IPV-Boostrix, administered 5 years after a first booster dose of IPV-Boostrix at 4 to 8 years of age, has been evaluated. One month post vaccination, > 99 % of subjects were seropositive against pertussis and seroprotected against diphtheria, tetanus and all three polio types.

 

The immunogenicity of Boostrix (dTpa component of IPV-Boostrix), administered 10 years after a first booster dose with reduced-antigen content diphtheria, tetanus and acellular pertussis vaccine(s) has been evaluated. One month post vaccination, > 99 % of subjects were seroprotected against diphtheria and tetanus and seropositive against pertussis.

 

After administration of one dose of IPV-Boostrix to 140 adults ³ 40 years of age that had not received any diphtheria and tetanus containing vaccine in the past 20 years, more than 96.4% of adults were seropositive for all three pertussis antigens and 77.7% and 95.7% were seroprotected against diphtheria and tetanus respectively.

 

Deleted the following statement:

The immunogenicity of revaccination with IPV-Boostrix has not been evaluated.

Updated on 18 February 2010 PIL

Reasons for updating

  • Change to product name

Updated on 4 September 2009 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 26 August 2009 PIL

Reasons for updating

  • New PIL for new product
  • New PIL for medicines.ie